amikacin sulfate / Generic mfg. - LARVOL DELTA

Preserving the Antimycobacterial Drug Arsenal: A Case Report of Disseminated Mycobacterium Avium Disease (IWLH 2026) - "The patient was treated with clarithromycin, ethambutol, rifabutin, moxifloxacin, and cycloserine for two years, with amikacin added for the first six months, inducing ototoxicity...A salvage regimen was initiated, including amikacin, tedizolid, clofazimine, ceftazidime/avibactam, isoniazid, delamanide, and ethambutol, as well as antiepileptic treatment and IFNγ administration...Intravenous dexamethasone was administered with intensified NTM treatment, but blood cell counts continued to decline, and inflammatory markers (CRP, PCT) remained high. Due to previous Gram-negative infections, his regimen was modified to include daptomycin, meropenem/vaborbactam, and colistimethate. Candida glabrata was identified in port cultures, necessitating port removal and initiation of isavuconazole. He was placed on dual beta-lactam therapy (meropenem and ceftriaxone) combined with clofazimine, isoniazid, linezolid, cycloserine, bedaquiline, and pretomanid...Conclusions This case..."

Case report • Clinical • CNS Disorders • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pulmonary Disease • Respiratory Diseases • Septic Shock • IFNG • IL12A

Pan-Resistant Pseudomonas aeruginosa Septic Shock in a Critically Ill Patient: A Case Report. (PubMed, Clin Med Insights Case Rep) - "Despite high-dose intravenous colistin, cefiderocol, and adjunctive amikacin, the infection persisted, leading to progressive multi-organ dysfunction...Meropenem (MIC 8 µg/mL; resistant) was trialed in combination with colistin for potential pharmacodynamic synergy...PDR Pseudomonas aeruginosa represents an urgent global threat. Until novel therapies become accessible, stringent stewardship, infection control, and preventive strategies remain the most effective defenses."

Journal • Chronic Kidney Disease • Critical care • Infectious Disease • Nephrology • Renal Disease • Respiratory Diseases • Septic Shock

Patient's features, clinical patterns and outcomes of non-tuberculous mycobacteria infections: A 10-year retrospective analysis from a third level university hospital. (PubMed, J Clin Tuberc Other Mycobact Dis) - "Attributable mortality was independently associated with older age, , previous tuberculosis, cancer, autoimmune disorders, and use of nebulized amikacin. NTM infections remain challenging to manage, particularly among patients with comorbidities and immunosuppression. Our findings highlight the need for individualized care strategies, multidisciplinary approach, improved diagnostics, and enhanced surveillance of NTM infections in Europe."

Journal • Retrospective data • Bronchiectasis • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Systemic Ebselen Treatment Prevents Amikacin Induced Ototoxicity and Nephrotoxicity in Mice (ARO 2026) - "Background : Aminoglycosides (AGs), such as tobramycin and amikacin, commonly used to treat recurrent pulmonary infections, are ototoxic and nephrotoxic. 28-days of amikacin increased the severity and duration of ototoxicity that was significantly reduced by ebselen. Amikacin-induced nephrotoxicity (increased Cr) was significantly reduced by ebselen. Interestingly, no hyperacusis was observed in any group and may be a consequence of greater PTS."

Preclinical • Infectious Disease • Nephrology • Otorhinolaryngology • Respiratory Diseases

Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing Klebsiella pneumoniae. (PubMed, Antimicrob Agents Chemother) - "Combination regimens with aminoglycosides (amikacin or plazomicin) occasionally demonstrated synergy using traditional definitions based on viable colony counting, but they were able to consistently reduce bacterial turbidity and the emergence of filamentous cells that were observed during exposure to ceftazidime/avibactam + aztreonam. Combinations between ceftazidime/avibactam, aztreonam, and an aminoglycoside are a potentially promising therapeutic strategy to combat the rising threat posed by MBL-producing K. pneumoniae."

Journal • Infectious Disease • Pneumonia

In vitro activity of mecillinam in combination with amikacin against carbapenemase-producing K. pneumoniae clinical isolates (ESCMID Global 2026) - No abstract available

Combination therapy • Preclinical • Infectious Disease • Pneumonia

Comparative evaluation of four antimicrobial susceptibility testing (AST) methods for amikacin among carbapenemase-producing K. pneumioniae clinical isolates (ESCMID Global 2026) - No abstract available

Clinical

Evaluation of ceftazidime/avibactam in combination with aztreonam, meropenem and amikacin in carbapenem-resistant Klebsiella pneumoniae strains and the distribution of carbapenemase-encoding genes (ESCMID Global 2026) - No abstract available

Combination therapy • Infectious Disease • Pneumonia

Development of a rapid actinomycetoma rapid in vitro susceptibility assay for determining the susceptibility towards amikacin, trimethoprim/sulfametoxazole and amoxicillin/clavulanic acid (AMAnTA) in actinomycetoma causative agents (ESCMID Global 2026) - No abstract available

Preclinical

In vitro activity of temocillin alone and in combination with amikacin against MDR K. pneumoniae strains: reversal of phenotypic resistance (ESCMID Global 2026) - No abstract available

Combination therapy • Preclinical • Infectious Disease • Pneumonia

In vitro activity of ceftazidime/avibactam combined with amikacin against difficult-to-treat resistant Pseudomonas aeruginosa (ESCMID Global 2026) - No abstract available

Preclinical

Acute kidney injury following amikacin therapy (ESCMID Global 2026) - No abstract available

Acute Kidney Injury • Nephrology • Renal Disease

Pharmacist-led implementation of Bayesian-based amikacin therapeutic drug monitoring in a Vietnamese tertiary hospital (ESCMID Global 2026) - No abstract available

Clinical

Potentiation of amikacin's bactericidal activity by mecillinam against carbapenem-resistant K.pneumoniae (ESCMID Global 2026) - No abstract available

Infectious Disease • Pneumonia

Population pharmacokinetic modelling and dosing optimisation of amikacin from birth to adolescence (ESCMID Global 2026) - No abstract available

Clinical • PK/PD data

Amikacin activity against carbapenem-resistant Klebsiella pneumoniae: impact of aminoglycoside-modifying enzymes in in vitro and in vivo models (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease • Pneumonia

Preliminary pharmacokinetic, safety, and tolerability data of the liposomal amikacin aerosol formulation for the treatment of Mycobacterium avium complex pulmonary disease (ESCMID Global 2026) - No abstract available

Clinical • PK/PD data • Pulmonary Disease • Respiratory Diseases

Exploring phage-amikacin combination against metallo-β-lactamase Gram-negative bacteria in a murine thigh infection model (ESCMID Global 2026) - No abstract available

Gram negative • Preclinical • Infectious Disease

A retrospective assessment of antimicrobial resistance patterns in WHO-access, watch, and reserve-classified antibiotics across two large hospitals in a resource-limited setting. (PubMed, Sci Rep) - "For the Access category, highest resistance was reported for Doxycycline at 100% resistance while the lowest resistance was reported for Amikacin at 24.63%. For the Watch category, the highest resistance was reported for Cefuroxime at 85.71% while the lowest resistance was reported for ticarcillin/clavulanic acid and Netilmicin, both with 0% resistance...More than 70% of multi-drug resistance was observed in frequently used antibiotics such as Cefuroxime, Ceftazidime, and Meropenem. Additionally, over 60% resistance was found in antibiotics like Ertapenem, Aztreonam, and Teicoplanin even though they are not readily available in Nigeria...Across gender, positive isolates were found more in women than men across almost all the microbes identified. These results, based on real patient data, highlight the urgent need for an institutionalized AWaRe Antibiotics framework across healthcare facilities in addition to broader strategies of antimicrobial stewardship, pharmaceutical..."

Journal • Retrospective data

Understanding the burden and impact of methicillin-resistant Staphylococcus aureus: exploring therapeutic options and hospital prevention strategies to improve patient outcome at the University Teaching Hospital of Kigali, Rwanda. (PubMed, Front Public Health) - "The isolates were highly resistant against commonly used antibiotics, including ampicillin (92.7%), erythromycin (49.3%), ciprofloxacin (42.3%), and tetracycline (48.5%). However, they demonstrated high sensitivity to vancomycin, linezolid, teicoplanin, amikacin, daptomycin, and rifampicin. Staphylococcus aureus infections are common at CHUK, with a high prevalence of MRSA (43%). Effective therapeutic options remain available, but the high resistance to commonly used antibiotics underscores the need for strengthened infection prevention measures and antimicrobial stewardship to improve patient outcomes, especially in critical care services."

Journal • Critical care • Infectious Disease

Mycobacterium abscessus lumbar osteomyelitis: A rare and challenging case with review of literature. (PubMed, IDCases) - "He was initially treated with IV amikacin, IV meropenem, IV tigecycline, and oral linezolid...He was discharged on IV tigecycline, imipenem, amikacin, and oral linezolid, later transitioning to oral omadacycline, azithromycin, and linezolid (Table 1). This case illustrates the challenges of managing Mycobacterium abscessus (MAB) infections, which require a multi-drug approach due to intrinsic and acquired antibiotic resistance. Therapy should begin with in-vitro guided IV antibiotics and transition to oral drugs for the continuation phase, optimizing therapeutic efficacy and overcoming resistance mechanisms."

Journal • Back Pain • Infectious Disease • Inflammation • Musculoskeletal Pain • Nontuberculous Mycobacterial Disease • Pain

Distribution characteristics of integrons and correlation analysis of antibiotic resistance in Aeromonas hydrophila. (PubMed, Front Cell Infect Microbiol) - "The integron-positive strains exhibited significantly higher resistance rates to ceftazidime, gentamicin, imipenem, trimethoprim-sulfamethoxazole, and amikacin compared to integron-negative strains (P < 0.05). These findings suggest that integrons, along with their carried resistance gene cassettes, could serve as useful molecular markers for epidemiological surveillance of multidrug-resistant Aeromonas hydrophila. Implementing routine screening for integrons and associated resistance genes in high-risk wards, such as hepatobiliary surgery, could enhance targeted infection control measures and help prevent the spread of resistant clones, including those of emerging pathogens like A. hydrophila."

Journal • Infectious Disease

Clinical Observation on the Efficacy of Urethral Dilation Combined with Bladder Instillation in the Treatment of Overactive Bladder in Female Patients (ChiCTR) - P=N/A | N=100 | Completed | Sponsor: The People's Hospital of Linxia; The People's Hospital of Linxia

New trial • Overactive Bladder

Multidrug-Resistant and Hypervirulent Listeria monocytogenes in Foods and Food-Processing Environments in Southern Brazil. (PubMed, Microb Pathog) - "Among 82 isolates, resistance was observed to clindamycin (CLI, 48.7%), meropenem (MER, 29.3%), sulfamethoxazole/trimethoprim (SUT, 29.3%), rifampicin (RIF, 14.6%), erythromycin (ERY, 10.9%), tetracycline (TET, 8.5%), streptomycin (STR, 7.3%), and amikacin (AMK, 4.9%). This study demonstrates the occurrence of L. monocytogenes isolates in foods and food-processing environments in southern Brazil that are resistant to clinically relevant antimicrobials, including multidrug resistance, and that also exhibit hypervirulent genotypes. The coexistence of antimicrobial resistance and hypervirulence in L. monocytogenes underscores the urgent need for continuous monitoring and control strategies to mitigate public health risks."

Journal

MM103 - Overlooked Risk: Ototoxicity Monitoring in Patients on Long-Term Azithromycin Therapy for Mycobacterium avium Complex Pulmonary Disease (AAA 2026) - "Core agents include macrolides (azithromycin or clarithromycin), ethambutol, and rifamycins (rifampin or rifabutin)...When aminoglycosides are introduced for macrolide-resistant disease, ototoxicity rates rise sharply, with hearing loss reported in 42% of patients treated with streptomycin and 27% treated with amikacin (Griffith et al., 2006)... Baseline and serial audiologic monitoring should be standard for patients with MAC, including those on macrolides. Interdisciplinary collaboration between infectious disease specialists and audiologists is essential for early detection, timely intervention, and patient counseling. This approach prevents irreversible hearing loss, supports treatment adherence, and improves overall patient outcomes.Brief Summary of Clinical Takeaways: The clinical takeaway for this session is to emphasize the importance of interdisciplinary collaboration between audiologists and infectious disease specialists in MAC management."

Clinical • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Nephrology • Nontuberculous Mycobacterial Disease • Otorhinolaryngology • Pulmonary Disease • Renal Disease • Respiratory Diseases